Status:

COMPLETED

Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Lead Sponsor:

SCRI Development Innovations, LLC

Collaborating Sponsors:

Bayer

Conditions:

Non-Hodgkins Lymphoma

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

In this multicenter trial, we will investigate the use of fludarabine plus rituximab, followed by Campath-1H, in previously untreated patients with CLL/SLL. Patients who are elderly, or who are consid...

Detailed Description

Upon determination of eligibility, all patients will receive: Fludarabine + Rituximab + CAMPATH-1H Patients who are judged by the investigator not to be candidates for fludarabine due to advanced ag...

Eligibility Criteria

Inclusion

  • To be included in this study, you must meet the following criteria:
  • Histologically proven B-cell CLL/SLL
  • Positive staining for CD20 antigen
  • No systemic chemotherapy.
  • Measurable or evaluable disease
  • Able to perform activities of daily living with minimal assistance
  • Age \> 18 years
  • Life expectancy \> 12 weeks
  • Adequate liver and kidney function
  • Must be accessible for treatment and follow-up
  • Must give written informed consent prior to entering this study.

Exclusion

  • You cannot participate in this study if any of the following apply to you:
  • Female pregnant or lactating
  • Unstabilized active infection on the basis of neutropenia
  • History of previous severe opportunistic infections
  • Serious underlying medical conditions
  • Central nervous system involvement
  • History of other neoplasms, either active or treated within five years
  • Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

Key Trial Info

Start Date :

January 1 2002

Trial Type :

INTERVENTIONAL

End Date :

April 1 2008

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT00193466

Start Date

January 1 2002

End Date

April 1 2008

Last Update

December 30 2010

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | DecenTrialz